​
​

Assertio (ASRT) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Assertio Revenue Highlights

Latest Revenue (Y)

$152.07M

Latest Revenue (Q)

$29.20M

Main Segment (Y)

Product

Main Geography (Y)

CANADA

Assertio Revenue by Period

Assertio Revenue by Year

DateRevenueChange
2023-12-31--2.67%
2022-12-31-40.73%
2021-12-31-4.46%
2020-12-31--53.69%
2019-12-31--26.39%
2018-12-31--18.11%
2017-12-31--16.49%
2016-12-31-33.02%
2015-12-31--12.20%
2014-12-31-190.87%
2013-12-31-47.78%
2012-12-31--31.70%
2011-12-31-64.64%
2010-12-31-39.90%
2009-12-31-65.69%
2008-12-31--46.87%
2007-12-31-586.63%
2006-12-31-116.81%
2005-12-31-2074.73%
2004-12-31--79.37%
2003-12-31--40.89%
2002-12-31--54.78%
2001-12-31-106.81%
2000-12-31-1440.16%
1999-12-31--85.58%
1998-12-31-33.33%
1997-12-31-100.00%
1996-12-31--

Assertio generated $152.07M in revenue during NA 2023, up -2.67% compared to the previous quarter, and up 48.78% compared to the same period a year ago.

Assertio Revenue by Quarter

DateRevenueChange
2024-09-30--6.17%
2024-06-30--4.07%
2024-03-31--1.63%
2023-12-31--7.42%
2023-09-30--13.09%
2023-06-30--3.47%
2023-03-31--15.66%
2022-12-31-47.18%
2022-09-30--2.62%
2022-06-30--3.85%
2022-03-31-9.62%
2021-12-31-30.85%
2021-09-30-0.39%
2021-06-30--5.46%
2021-03-31--11.06%
2020-12-31--12.70%
2020-09-30-67.65%
2020-06-30--1.43%
2020-03-31--64.68%
2019-12-31-7.40%
2019-09-30--3.59%
2019-06-30--1.25%
2019-03-31-35.99%
2018-12-31--45.03%
2018-09-30-22.47%
2018-06-30--50.72%
2018-03-31-36.01%
2017-12-31--1.05%
2017-09-30--5.02%
2017-06-30-11.07%
2017-03-31--27.01%
2016-12-31-12.11%
2016-09-30--5.28%
2016-06-30-11.36%
2016-03-31--5.75%
2015-12-31-6.02%
2015-09-30-10.95%
2015-06-30-193.46%
2015-03-31--83.45%
2014-12-31-277.98%
2014-09-30--23.99%
2014-06-30--11.51%
2014-03-31-88.49%
2013-12-31-8.41%
2013-09-30-25.02%
2013-06-30-14.48%
2013-03-31--1.56%
2012-12-31--20.11%
2012-09-30-135.88%
2012-06-30--16.19%
2012-03-31-38.77%
2011-12-31--26.57%
2011-09-30--22.13%
2011-06-30--74.47%
2011-03-31-298.39%
2010-12-31-3.64%
2010-09-30--17.58%
2010-06-30-58.98%
2010-03-31-16.06%
2009-12-31--42.50%
2009-09-30-98.26%
2009-06-30-17.59%
2009-03-31-13.28%
2008-12-31--38.24%
2008-09-30-123.45%
2008-06-30-10.77%
2008-03-31-7.87%
2007-12-31--

Assertio generated $29.20M in revenue during Q3 2024, up -6.17% compared to the previous quarter, and up 71.24% compared to the same period a year ago.

Assertio Revenue Breakdown

Assertio Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 22Dec 21Dec 20
C A M B I A---
Other Revenue---
Zipsor---
SPRIX Nasal Spray---
Royalties And Milestones---
Product, Other---
Product---
Otrexup---
INDOCIN Products---
Product and Service, Other---
Commercialization Agreement---

Assertio's latest annual revenue breakdown by segment (product or service), as of Dec 22: Product (50.11%), INDOCIN Products (32.41%), C A M B I A (7.98%), Otrexup (3.60%), SPRIX Nasal Spray (2.94%), Product, Other (1.51%), Zipsor (1.09%), Royalties And Milestones (0.78%), and Other Revenue (-0.42%).

Quarterly Revenue by Product

Product/ServiceSep 24Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20
Royalties And Milestones---------------
Product---------------
Otrexup---------------
INDOCIN Products---------------
CAMBIA---------------
SPRIX Nasal Spray---------------
Product, Other---------------
Otrexup Acquisition---------------
Product and Service, Other---------------
Zipsor---------------
C A M B I A---------------
Commercialization Agreement---------------
Commercialization Rights And Facilitation Services---------------
SOLUMATRIX Products---------------
Gralise---------------
Janssen Nucynta---------------
OXAYDO---------------

Assertio's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Product (71.32%), INDOCIN Products (14.09%), SPRIX Nasal Spray (4.96%), Otrexup (4.47%), CAMBIA (3.39%), Royalties And Milestones (1.24%), and Product, Other (0.53%).

Assertio Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 22Dec 21Dec 20
CANADA---

Assertio's latest annual revenue breakdown by geography, as of Dec 22: CANADA (100.00%).

Quarterly Revenue by Country

CountrySep 24Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 20Sep 20
CANADA----------

Assertio's latest quarterly revenue breakdown by geography, as of Sep 24: CANADA (100.00%).

Assertio Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
RDYDr. Reddy's Laboratories--
CTLTCatalent--
AMRXAmneal Pharmaceuticals--
NBIXNeurocrine Biosciences--
ALKSAlkermes--
PCRXPacira BioSciences--
AMPHAmphastar Pharmaceuticals--
COLLCollegium Pharmaceutical--
ANIPANI Pharmaceuticals--
ITCIIntra-Cellular Therapies--
IRWDIronwood Pharmaceuticals--
EGRXEagle Pharmaceuticals--
EOLSEvolus--
DCPHDeciphera Pharmaceuticals--
ASRTAssertio--
LFCRLifecore Biomedical--
ESPREsperion Therapeutics--
ALVOAlvotech--
AGRXAgile Therapeutics--
ACRXTalphera--

ASRT Revenue FAQ

What is Assertio’s yearly revenue?

Assertio's yearly revenue for 2023 was $152.07M, representing a decrease of -2.67% compared to 2022. The company's yearly revenue for 2022 was $156.23M, representing an increase of 40.73% compared to 2021. ASRT's yearly revenue for 2021 was $111.01M, representing an increase of 4.46% compared to 2020.

What is Assertio’s quarterly revenue?

Assertio's quarterly revenue for Q3 2024 was $29.2M, a -6.17% decrease from the previous quarter (Q2 2024), and a -18.03% decrease year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $31.13M, a -4.07% decrease from the previous quarter (Q1 2024), and a -24.07% decrease year-over-year (Q2 2023). ASRT's quarterly revenue for Q1 2024 was $32.45M, a -1.63% decrease from the previous quarter (Q4 2023), and a -23.59% decrease year-over-year (Q1 2023).

What is Assertio’s revenue growth rate?

Assertio's revenue growth rate for the last 3 years (2021-2023) was 36.98%, and for the last 5 years (2019-2023) was -33.74%.

What are Assertio’s revenue streams?

Assertio's revenue streams in c 22 are C A M B I A, Other Revenue, Zipsor, SPRIX Nasal Spray, Royalties And Milestones, Product, Other, Product, Otrexup, and INDOCIN Products. C A M B I A generated $24.72M in revenue, accounting 7.98% of the company's total revenue, down -1.01% year-over-year. Other Revenue generated $-1.29M in revenue, accounting -0.42% of the company's total revenue, up 30.96% year-over-year. Zipsor generated $3.36M in revenue, accounting 1.09% of the company's total revenue, down -66.97% year-over-year. SPRIX Nasal Spray generated $9.11M in revenue, accounting 2.94% of the company's total revenue, up 5.00% year-over-year. Royalties And Milestones generated $2.4M in revenue, accounting 0.78% of the company's total revenue, down -6.82% year-over-year. Product, Other generated $4.67M in revenue, accounting 1.51% of the company's total revenue, down -7.10% year-over-year. Product generated $155.12M in revenue, accounting 50.11% of the company's total revenue, up 41.77% year-over-year. Otrexup generated $11.15M in revenue, accounting 3.60% of the company's total revenue INDOCIN Products generated $100.34M in revenue, accounting 32.41% of the company's total revenue, up 65.69% year-over-year.

What is Assertio’s main source of revenue?

For the fiscal year ending Dec 22, the largest source of revenue of Assertio was Product. This segment made a revenue of $155.12M, representing 50.11% of the company's total revenue.